Ann-Lii Cheng
National Taiwan University
CancerInternal medicineSurgeryPathologyOncologyApoptosisImmunologyChemotherapyCarcinomaHepatocellular carcinomaSorafenibLymphomaIn patientPhases of clinical researchCancer researchBreast cancerMedicineBiologyGastroenterologyPharmacology
Publications 751
#1Robin Kate Kelley (UCSF: University of California, San Francisco)H-Index: 36
#2Rebecca A. Miksad (BMC: Boston Medical Center)H-Index: 28
Last. Suvajit Sen (Exelixis)H-Index: 12
view all 14 authors...
Albumin-bilirubin (ALBI) grade is an objective measure of liver function for patients with hepatocellular carcinoma (HCC). The tyrosine kinase inhibitor cabozantinib is approved for patients with advanced HCC who have received prior sorafenib based on the phase 3 CELESTIAL trial (NCT01908426). Cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated HCC. Patients were randomised 2:1 to receive cabozantinib 60 mg or placebo...
#1Shih-Hung Yang (NTU: National Taiwan University)H-Index: 13
#2Li-Chun Lu (NTU: National Taiwan University)H-Index: 13
Last. Kun-Huei Yeh (NTU: National Taiwan University)H-Index: 35
view all 10 authors...
Immune checkpoint inhibitors have limited efficacy in the treatment of pancreatic ductal adenocarcinoma (PDAC). We investigated prognostic markers for nivolumab-based therapy in advanced or recurrent PDAC. Consecutive patients receiving nivolumab-based therapy at our institution between 2015 and 2020 were evaluated. Overall survival (OS) was analyzed through univariate and multivariate analyses. Spleen volume was estimated from the width, thickness, and length of the spleen. A total of 45 patien...
#1Lipika GoyalH-Index: 28
#2Arndt VogelH-Index: 55
Last. Abby B. SiegelH-Index: 28
view all 11 authors...
#1Tim F. GretenH-Index: 71
#2Ghassan K. Abou-Alfa (Cornell University)H-Index: 52
Last. Ahmed Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 29
view all 21 authors...
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Immunothera...
#1Ta Chen Huang (NTU: National Taiwan University)H-Index: 1
#2Cher-Wei Liang (FJU: Fu Jen Catholic University)H-Index: 15
Last. Chih-Hung Hsu (NTU: National Taiwan University)H-Index: 43
view all 8 authors...
Purpose null Programmed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells. null Methods null Archival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (ESCC) in three prospective phase II t...
#1George Lau (Chinese PLA General Hospital)H-Index: 6
#2Ming-Lung Yu (KMU: Kaohsiung Medical University)H-Index: 60
Last. Gregory Cheng (Chinese PLA General Hospital)H-Index: 7
view all 30 authors...
Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from ...
1 CitationsSource
#1Bang-Bin Chen (NTU: National Taiwan University)H-Index: 17
#2Yu-Yun Shao (NTU: National Taiwan University)H-Index: 24
Last. Tiffany Ting-Fang Shih (NTU: National Taiwan University)H-Index: 30
view all 8 authors...
Objective: This study assessed dynamic contrast-enhanced (DCE)-MRI and intravoxel incoherent motion diffusion-weighted imaging (IVIM DWI) parameters to prospectively predict survival outcomes in participants with advanced hepatocellular carcinoma (HCC) who received lenalidomide, a dual antiangiogenic and immunomodulatory agent, as second-line therapy in a Phase II clinical trial. Materials and methods: Forty-four participants with advanced HCC who had progression after sorafenib as first-line tr...
#1Ying-Chun Shen (NTU: National Taiwan University)H-Index: 19
#2Pei-Chang Lee (NYMU: National Yang-Ming University)H-Index: 6
Last. Zhong-Zhe Lin (NTU: National Taiwan University)H-Index: 17
view all 17 authors...
Background null Gut microbiome has been associated with the efficacy of immune checkpoint inhibitors (ICI) in patients with various types of cancers but not yet in hepatocellular carcinoma (HCC). null Aims null To investigate the association between gut microbiome and efficacy of ICI in patients with HCC. null Methods null Patients with HCC who were scheduled to receive ICI were prospectively enrolled. Fecal samples were collected within 7 days before initiation of ICI (baseline) and 8 weeks lat...
#1Robin Kate Kelley (UCSF: University of California, San Francisco)H-Index: 36
#2Bruno Sangro (University of Navarra)H-Index: 77
Last. Thomas Yau (QMUL: Queen Mary University of London)H-Index: 43
view all 24 authors...
PURPOSEThis phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monot...
4 CitationsSource